Extensive efforts have been undertaken to discover the underlying mechanisms behind the relatively low response in certain patients, and a number of factors have been identified to be associated with ICI efficacy, such as baseline PD-L1 expression in tumor cells, host genetics, and the profile of tumor-infiltrating lymphocytes [4]. The gene discussed is CD274; the disease is neoplasm.